ArticleEuropean journal of medical research2022
Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes.
Article in European journal of medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association between the atherogenic index of plasma and metabolic-associated/nonalcoholic fatty liver disease: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Association between atherogenic index of plasma and various metabolic conditions: an umbrella review on meta-analyses.BMC cardiovascular disorders · 2025Pooled it
- Article
- Association between atherogenic index of plasma and MASLD in patients with type 2 diabetes: a cross-sectional study.BMC endocrine disorders · 2026Article
- MASH in Type 2 Diabetes: Pathophysiology, Diagnosis, and Therapeutic Management-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Comparing the diagnostic performance of metabolic indices in metabolic dysfunction-associated fatty liver disease patients: a retrospective cross-sectional study.European journal of medical research · 2026Article
- Article
- Atherogenic index of plasma as a simple marker for NAFLD risk stratification in community-dwelling older adults: a cross-sectional study with incremental predictive value assessment.Frontiers in endocrinology · 2026Article
- Newer laboratory indices for identification of metabolic dysfunction-associated steatotic liver disease in obesity.Journal of family medicine and primary care · 2025Article
- Atherogenic index of plasma identifies subjects with severe liver steatosis.Scientific reports · 2025Article
- Atherogenic indices and risk of chronic kidney disease in metabolic derangements: Gangnam Severance Medical Cohort.Kidney research and clinical practice · 2025Article
- Atherogenic Combined Index is Independently Associated with MASLD in Type 2 Diabetes: A Cross-Sectional Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Association between the atherogenic index of plasma and mortality in the chronic kidney disease population: evidence from NHANES.Frontiers in medicine · 2025Article
- Association between the atherogenic index of plasma and testosterone deficiency in American adults: a cross-sectional study from NHANES 2011-2016.Frontiers in endocrinology · 2025Article
- Exposure of cumulative atherogenic index of plasma and the development of prediabetes in middle-aged and elderly individuals: evidence from the CHARLS cohort study.Cardiovascular diabetology · 2024Article
- Association between atherogenic index of plasma and new-onset stroke in individuals with different glucose metabolism status: insights from CHARLS.Cardiovascular diabetology · 2024Article
- Assessment of Serum Atherogenic Indices and Insulin Resistance in Retinal Vein Occlusion.Turkish journal of ophthalmology · 2024Article
- Using new indices to predict metabolism dysfunction-associated fatty liver disease (MAFLD): analysis of the national health and nutrition examination survey database.BMC gastroenterology · 2024Article
- Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis.Vascular pharmacology · 2024Review
- Elevated AIP is associated with the prevalence of MAFLD in the US adults: evidence from NHANES 2017-2018.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease, is the leading cause of liver disease that can ultimately lead to cirrhosis. Identifying a screening marker for early diagnosis of MAFLD in patients with type 2 diabetes (T2D) can reduce the risk of morbidity and mortality. This study investigated the association between the atherogenic index of plasma (AIP) and MAFLD in patients with T2D.
methodA retrospective case-control study was conducted and medical records of patients with T2D were assessed. The baseline characteristics, anthropometric indices, laboratory measurements including liver functions tests, fasting blood sugar, HbA1C, lipid profile were documented.
resultsOut of 2547 patients with T2D, 824 (32.4%) had MAFLD. The multivariate logistic regression analysis showed a significant difference in female-to-male ratio (1.11 vs. 1.33, OR = 0.347, P-value < 0.001), ALT (42.5 ± 28.1 vs. 22.4 ± 11.1, OR = 1.057, P-value < 0.001), and AIP (0.6 ± 0.3 vs. 0.5 ± 0.3, OR = 5.057, P-value < 0.001) between MAFLD and non-MAFLD groups, respectively. According to the AIP quartile, the prevalence of MAFLD increased significantly in patients with higher AIP quartiles (P-value < 0.001). Also, we found a cut-off of 0.54 for AIP in predicting MAFLD in patients with T2D (sensitivity = 57.8%, specificity = 54.4%).
conclusionIn this study, we found that AIP is a good and independent predictor for MAFLD in patients with T2D which could help physicians in early diagnosis and follow-up of patients with T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.